Skip to main content
TipRanks
Go Ultimate75% OFF

Rua Bioscience Ltd. (RUA) AI Stock Analysis

1 Followers
NZ:RUA

Rua Bioscience Ltd.

(NZX:RUA)

Select Model
Rating:44Neutral
Price Target:NZD 0.02â–¼(-7.69% Downside)
Action:initiatedcoverage
Date:10/05/26

The score is primarily held down by weak financial performance, driven by persistent large losses and ongoing cash burn despite improving revenue. Technicals also add pressure, with the price below key moving averages and negative MACD indicating a weak trend. Valuation contributes only modestly because the negative P/E reflects losses and there is no dividend yield support.

Positive Factors
Revenue GrowthRevenue has continued to scale across the reported periods, indicating that the company is expanding sales despite its difficult earnings profile. Sustained top-line growth can improve operating leverage over time if Rua converts increased product demand into better margins and cash generation.
Negative Factors
Persistent LossesPersistent large losses and deeply negative net margins show that revenue growth has not yet translated into an economically sustainable business. This weak earnings base limits internal funding, increases dependence on external capital, and makes future profitability highly sensitive to cost and pricing improvements.

Rua Bioscience Ltd. (RUA) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%50%NZ:RUA-7.14%SPY+8.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
NZD 6.91M
Dividend Yield
―
Average Volume (3M)
87.52K
Price to Earnings (P/E)
-2.6
Beta (1Y)
1.23
Revenue Growth
70.82%
EPS Growth
41.04%
Country
NZ
Employees
15
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Rua Bioscience Ltd. Business Overview & Revenue Model

Company Description

Rua Bioscience Limited, a company founded in 2016 and headquartered in Gisborne, New Zealand, is dedicated to the investigation, refinement, and production of medicinal products for both the New Zealand market and international distribution. Their of...

Rua Bioscience Ltd. Financial Statement Overview

Summary

Revenue is growing (about +21% in 2025 and +10% in 2026), but profitability remains extremely weak with large, persistent net losses and deeply negative net margins. Cash flow is also consistently negative with ongoing operating and free cash flow burn. The balance sheet is relatively steadier with positive equity and only moderate leverage, though debt has risen and ROE is sharply negative.

Income Statement

18Very Negative

Balance Sheet

52Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue2.58M2.58M1.90M85.84K357.68K24.23K
Gross Profit-2.52M-1.26M923.23K-118.31K18.12K-5.22M
EBITDA-3.44M-2.96M-2.86M-13.30M-5.25M-6.63M
Net Income-3.36M-3.36M-3.46M-13.72M-5.96M-8.64M
Balance Sheet
Total Assets7.17M7.17M6.77M7.74M20.95M33.57M
Cash, Cash Equivalents and Short-Term Investments533.70K533.70K241.42K895.13K4.56M9.94M
Total Debt1.76M1.76M735.60K147.78K114.58K824.00K
Total Liabilities2.92M2.92M1.88M973.13K830.31K9.38M
Stockholders Equity4.25M4.25M4.89M6.77M20.12M24.20M
Cash Flow
Free Cash Flow0-3.02M-2.72M-3.60M-5.80M-7.18M
Operating Cash Flow-3.02M-3.02M-2.72M-3.60M-5.73M-6.78M
Investing Cash Flow-302-302105.76K2.21M6.67M5.59M
Financing Cash Flow3.31M3.31M1.95M-94.78K-120.38K-208.64K

Rua Bioscience Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.03

Price Trends

50DMA0.03Negative
100DMA0.03Negative
200DMA0.03Negative

Market Momentum

MACD0.00Negative
RSI51.12Neutral
STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:RUA, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 51.12 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:RUA.

Rua Bioscience Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NZ:RUA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NZ:PHLNZ:PHL63NeutralNZD 33.62M0.03――15.19%1154.17%
NZ:BLTNZ:BLT61NeutralNZD 31.98M50.00――16.01%-28.57%
NZ:TAHNZ:TAH58NeutralNZD 37.83M11.70―4.21%21.56%18.96%
NZ:AFTNZ:AFT54NeutralNZD 485.57M32.3914.07%0.64%22.44%23.14%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NZ:RUANZ:RUA44NeutralNZD 11.77M-2.60――70.82%41.04%

* Healthcare Sector Average

Performance Comparison

0%50%NZ:RUANZ:AFTNZ:BLTNZ:PHLNZ:TAHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NZ:RUA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NZ:RUARua Bioscience Ltd.0.03-0.00-3.70%
NZ:AFTAFT Pharmaceuticals Ltd.4.630.9726.47%
NZ:BLTBLIS Technologies Limited0.030.0166.67%
NZ:PHLPromisia Healthcare Limited0.620.0611.71%
NZ:TAHThird Age Health Services Limited3.80-1.80-32.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 05, 2026